Trissel Lawrence A, Xu Quanyun A
Clinical Pharmaceutics Research, Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center.
Int J Pharm Compd. 2005 May-Jun;9(3):238-41.
The objective of this study was to evaluate the physical and chemical stabilty of undiluted palonosetron hydrochloride 50 micrograms/mL in combination with topotecan hydrochloride 0.1 mg/mL or irinotecan hydrochloride 1 mg/mL in 5% dextrose injection during simulated Y-site administration. Triplicate test samples were prepared by admixing 5 mL of palonosetron hydrochloride with 5 mL of the topotecan hydrochloride or irinotecan hydrochloride admixture. Physical stabilty was assessed by using a multistep evaluation preocdure that included both turbidimetric and particulate measurement as well as visual inspection. Chemical stability was assessed by using stability-indicating high-performance liquid chromatographic analytical techniques to determine drug concentrations. Evaluations were performed initially upon mixing and again 1 and 4 hour after mixing. The palonosetron hydrochloride-topotecan hydrochloride samples were clear and pale yellow when viewed in normal fluorescent room light. When viewed with a Tyndall beam, the samples had a slight haziness. The palonosetron hydrochloride-irinotecan hydrochloride samples were clear and colorless when viewed in in normal fluorescent room light and with a Tyndall beam. Measured turbidities remained unchanged; particulate contents were low and changed little. High-performance liquid chromatographic analysis found that palonosetron hydrochloride, topotecan hydrochloride, and irinotecan hydrochloride remained stable throughout the 4-hour test. Little drug loss was observed. Palonosetron hydrochloride is physically compatible and chemically stable with topotecan hydrochloride and with irinotecan hydrochloride during Y-site administration.
本研究的目的是评估在模拟Y型给药过程中,50微克/毫升盐酸帕洛诺司琼与0.1毫克/毫升盐酸拓扑替康或1毫克/毫升盐酸伊立替康在5%葡萄糖注射液中未稀释混合液的物理和化学稳定性。通过将5毫升盐酸帕洛诺司琼与5毫升盐酸拓扑替康或盐酸伊立替康混合液混合制备一式三份的测试样品。物理稳定性通过多步骤评估程序进行评估,该程序包括比浊法和微粒测量以及目视检查。化学稳定性通过使用稳定性指示高效液相色谱分析技术来测定药物浓度进行评估。最初在混合时进行评估,混合后1小时和4小时再次评估。在正常荧光室内光线下观察,盐酸帕洛诺司琼-盐酸拓扑替康样品清澈且呈浅黄色。用廷德尔光束观察时,样品有轻微浑浊。在正常荧光室内光线下和用廷德尔光束观察时,盐酸帕洛诺司琼-盐酸伊立替康样品清澈无色。测得的浊度保持不变;微粒含量低且变化不大。高效液相色谱分析发现,在4小时的测试过程中,盐酸帕洛诺司琼、盐酸拓扑替康和盐酸伊立替康保持稳定。观察到药物损失很少。在Y型给药过程中,盐酸帕洛诺司琼与盐酸拓扑替康以及与盐酸伊立替康在物理上相容且化学稳定。